Abionyx Pharma shares gained ground on the Paris Bourse on Tuesday, after reporting encouraging new results in uveitis, a recurrent inflammatory disease of the eye.

According to these preclinical studies, 'statistically significant' differences were observed six hours after injection for groups treated with its CER-001 alone or in combination with a corticosteroid, showing a reduction in severe inflammation.

A total of 74 subjects took part in the study.

Abionyx also announced on Tuesday the appointment of Jérôme Martinez, former president of French operations for Japanese pharmaceutical company Santen, as senior advisor in ophthalmology.

At 12:30 pm, the share price was down 0.7%, bringing its year-to-date decline to over 27%.

Copyright (c) 2023 CercleFinance.com. All rights reserved.